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Case of Multiple Sulfatase Deficiency and
Ocular Albinism: A Diagnostic Odyssey
Chitra Prasad, C. Anthony Rupar, Craig Campbell, Melanie Napier,
David Ramsay, K.Y. Tay, Sapna Sharan, Asuri N. Prasad
ABSTRACT: Background: Multiple sulfatase deficiency (MSD) is a rare autosomal recessive inborn error of lysosomal metabolism.
The clinical phenotypic spectrum encompasses overlapping features of variable severity and is suggestive of individual single sulfatase
deficiencies (i.e., metachromatic leukodystrophy, mucopolysaccharidosis, and X-linked ichthyosis). Case Report: We describe a 3-yearold male with severe hypotonia, developmental regression and progressive neurodegeneration, coarse facial features, nystagmus (from
ocular albinism), and dysmyelinating motor sensory neuropathy. Ethics approval was obtained from the Western University Ontario.
Results: Extensive investigative work-up identified deficiencies of multiple sulfatases: heparan sulfate sulfamidase: 6.5 nmoles/mg/
protein/17 hour (reference 25.0-75.0), iduronate-2-sulfate sulfatase: 9 nmol/mg/protein/4 hour (reference 31-110), and arylsulfatase A: 3.8
nmoles/hr/mg protein (reference 22-50). The identification of compound heterozygous pathogenic mutations in the SUMF1 gene c.836
C > T (p.A279V) and c.1045C > T (p.R349W) confirmed the diagnosis of MSD. Conclusion: The complex clinical manifestations of
MSD and the unrelated coexistence of ocular albinism as in our case can delay diagnosis. Genetic counselling should be provided to all
affected families.

RÉSUMÉ: Patient atteint d’un déficit multiple en sulfatases et d’albinisme oculaire: odyssée diagnostique. Contexte: Le déficit multiple en
sulfatases est une erreur innée du métabolisme. Cette maladie enzymatique rare est transmise de façon autosomique récessive. Le spectre phénotypique
clinique inclut des manifestations de sévérité variable qui se chevauchent et il évoque le tableau de déficiences simples en sulfatases (c.-à-d. la
leucodystrophie métachromatique, la mucopolysaccharidose et l’ichthyose liée à l’X). Observation clinique: Nous décrivons la présentation clinique d’un
garçonnet de 3 ans atteint d’une hypotonie sévère, d’une régression développementale et d’une neurodégénérescence progressive et présentant des traits
grossiers du visage, un nystagmus (dû à l’albinisme oculaire) et une neuropathie sensitivo-motrice démyélinisante. Une approbation éthique a été obtenue
de la Western University en Ontario. Résultats: Une démarche diagnostique approfondie nous a permis d’identifier des déficits multiples en sulfatases:
sulfamidase de l’héparane sulfate: 6,5 nmol/mg de protéine/17 heures (valeurs de référence 25,0 à 75,0), sulfatase de l’iduronate-2-sulfate: 9 nmol/mg de
protéine/4 heures (valeurs de référence 31 à 110) et arylsulfatase A: 3,8 nmol/heure/mg de protéine (valeurs de référence 22 à 50). L’identification de deux
mutations pathogéniques dans le gène SUMF1 c. 836 C > T (p.A279V) et c. 1045 C > T (p.R349W) chez le patient a confirmé le diagnostic de déficit
multiple en sulfatases et son statut d’hétérozygote composé. Conclusion: Les manifestations cliniques complexes du déficit multiple en sulfatases et la
coexistence non reliée de l’albinisme oculaire, telles que présentes chez notre patient, peuvent retarder le diagnostic. Toutes les familles atteintes de cette
maladie devraient bénéficier d’un conseil génétique.

Keywords: Multiple sulfatase deficiency, mucopolysaccharidosis, metachromatic leukodystrophy, developmental regression and ocular
albinism
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INTRODUCTION
Multiple sulfatase deficiency (MSD; MIM#272200) is one of
the rarest lysosomal disorders, with fewer than 50 published
cases.1 MSD is also referred to as Austin disease,2 who first
described it as a form of metachromatic leukodystrophy. The
clinical phenotype varies in severity and encompasses features
of single sulfatase deficiencies: metachromatic leukodystrophy;
mucopolysaccharidoses II, IIIA, IIID, IVA, and VI; X-linked
ichthyosis; and chondrodysplasia punctata.3 Age-dependent
presentations of MSD are categorized into the neonatal,4 late
infantile, and infantile and juvenile forms.5
Seventeen sulfatases are encoded in the human genome, eight
of which are associated with diseases resulting from single

626
https://doi.org/10.1017/cjn.2014.12 Published online by Cambridge University Press

Can J Neurol Sci. 2014; 41: 626-631

sulfatase deficiencies.6 Sulfatases are necessary for nonredundant
desulfation of glycosaminoglycans and sulfatides in lysosomes
and steroid sulfates in the endoplasmic reticulum. All human
sulfatases have a related biochemical function, as evident from
sequence comparison, and share a common control of their
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activity. Several human sulfatases play a role in the normal
functioning of the central nervous system. The primary defect in
MSD lies in the unique posttranslational activation of newly
synthesized sulfatases by the formylglycine-generating enzyme
(FGE).7 FGE, the protein product of the SUMF1 gene, belongs to
a previously identified protein family classified as having
“unknown function.” SUMF1 is both an essential and a limiting
factor for sulfatases.8,9 Human FGE forms the bottleneck in the
activation of all sulfatases.7,10,11 Both residual enzyme activity
and protein stability of mutant FGE contribute to the clinical
phenotype of MSD.10,12 There may be additional factors
influencing FGE function acting as disease modifiers.
CASE REPORT
A 26-month-old boy presented to the Neurometabolic clinic at
our institution (Children’s Hospital, London Health Sciences
Centre) with severe generalized hypotonia. His parents were
nonconsanguineous and of Caucasian ethnic background. He was
born at 41 weeks’ gestation by spontaneous vaginal delivery with
a birth weight of 4 kg (75th-70th centile). At the age of 4 months,
impairment in visual fixation and tracking were detected. Poor
head control, poor suck, and recurrent episodes of vomiting
and pneumonia were also present. He was initially seen in an
ophthalmology clinic for his parents’ visual concerns. He had
clinical features of ocular albinism, namely photophobia, foveal
hypoplasia, and iris trans-illumination defects. Visual evoked
responses showed chiasmal misrouting. Molecular genetic testing
was done in an ophthalmology clinic for pathogenic mutations of
ocular albinism and Chediak Higashi syndrome (because his
ocular albinism was thought to be complex); this testing did not
detect pathogenic mutations. The mother’s eye examination
also revealed iris trans-illumination, typical in ocular albinism.

However, her fundus was normal. There was no history of
seizures or skin rashes in the proband. Developmentally, he was
able to roll over supine to prone at 7 months of age. At 15 months,
he could commando crawl along the floor with his arms; however,
he was unable to crawl using all four limbs. At 22 months, he was
able to sit independently and pull-to-stand. He never developed
the ability to cruise or walk. Approximately 2 months before his
presentation, a decline in his motor skills was noted. At 3 years, he
was unable to sit independently. He could no longer pull himself
along the floor or pull himself to stand. By parental report, he lost
head control and was unable to maintain head posture. At presentation, he had a palmar grasp and by report had lost the skill of
a pincer grasp in the use of his hands. He did transfer objects
between hands, but could not hold a pencil or scribble. In the
domain of speech and language, he was nonverbal. The parents
felt that he did make some consonant sounds and possibly
responded to his own name being called. In regard to social skills
he had a social smile and could laugh. He played peek-a-boo. He
brought objects to his mouth for oral exploration. He was able to
feed himself with finger foods; however, his parents felt that he
was losing this ability and tended to spill food easily. At the age
of 3 year and 3 months, he had regressed significantly and was
performing at around a less than 6 month age level.
On examination at 3 years, his weight was 13.6 kg (10th centile), length was 90 cm (3rd centile), and head circumference was
52 cm (50th-95th centile). He had relatively coarse facial features
with slight hypertelorism, flat nasal bridge, low set posteriorly
rotated ears, small mouth, and mild left eye ptosis (Figure 1a;
taken at age 1 year).
At 3 years, he was able to fix and follow objects in close
proximity. Visual saccades and smooth pursuit movements were
barely detectable. Speech and language development was limited
to nonspecific vocalizations. He had very fine nystagmus in both

Figure 1: (a) Front view of the patient at age 1 year showing slight coarse facies, mild
hypertelorism, and mild left eye ptosis. He is able to sit with minimal support and appears
socially appropriate. (b) Front view of the patient at 4 years and 8 months. He is wheelchair
bound, is unable to focus, and is nonresponsive to his surroundings.
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eyes and no corneal clouding. There were no other bony or limb
abnormalities, no skin ichthyosis, and no heart involvement. His
thumbs were slightly short. Organomegaly was not present. Motor
examination disclosed significant head lag, severe generalized
hypotonia, and hypoactive to absent deep tendon reflexes. He was
unable to sit without support. Fine motor skills were limited to
only primitive grasp. Socially, he had poor interactive skills.
Motor and sensory nerve conduction velocities were slow and in
keeping with a dysmyelinating motor sensory neuropathy on
nerve conduction studies (NCS). Currently, the patient has a
gastrostomy tube for feeding and has been receiving palliative
care since the age of 3 years and 9 months. At present, he is
completely nonresponsive, having lost speech and language
vocalization and all of his gross motor and fine motor skills
(Figure 1b; taken at age 4 years and 8 months). Recently, he was
also found to have significant generalized ichthyosis, which
required the frequent use of skin-moistening creams and lotions.
RESULTS
Biochemical Testing
Plasma very long chain fatty acids, lactate levels, and transferrin isoelectric focusing were normal. Urine for mucopolysaccharides showed mild elevations at 20.5 mg/mmol creatinine
(reference 3.6-13.4 mg/mmol creatinine), with heparan sulfate
predominating. Further urine analysis confirmed the presence of
sulfatides. The activities of other sulfatases were low in fibroblasts: heparan sulfate sulfamidase, 6.5 nmoles/mg/protein/
17 hour (reference 25.0-75.0); iduronate-2-sulfate sulfatase,
9 nmol/mg/protein/4 hour (reference 31-110); and arylsulfatase A,
3.8 nmoles/hr/mg protein (reference 22-50). The activities of other
lysosomal enzymes including α-glucosidase, β-galactocerebrosidase,
and β-galactosidase were all normal.
Pathology
Electron microscopic examination of skin fibroblasts revealed
nonspecific pleomorphic lysosomal inclusions in the Schwann

cells (Figures 2a and 2b).13 The other cytological elements in the
biopsy, including fibroblasts, sweat ducts, and vascular endothelial cells and smooth muscle were ultrastructurally unremarkable.
Cranial Imaging and Skeletal Survey
A skeletal survey showed the presence of ovoid lumbar vertebral
bodies suggestive of storage disease. Cranial MRI at the age of
2 years and 11 months demonstrated bilateral symmetrical white
matter hyperintensities sparing the subcortical U-fibers on the
T2-weighted fluid-attenuated inversion recovery sequence. Cranial
MRI was normal at age 11 months. This supports the hypothesis that
white matter signal abnormalities are due to dysmyelination induced
demyelination (Figures 3a, 3b; Figures 4a, 4b).
Molecular Testing
Array comparative genomic hybridization and molecular testing
for Pelizaeus-Merzbacher disease were negative. He was homozygous for the ARSA pseudodeficiency alleles p.N352S and
c.*96A > G. Two previously described mutations in SUMF1 were
identified—c.836 C > T (p.A279V) and c.1045C > T (p.R349W)—
confirming the diagnosis of MSD.
DISCUSSION
In our patient, the presence of ocular albinism was the focus of
the initial investigative work-up through an ophthalmology clinic.
Chiasmal misrouting was surmised to be due to ocular albinism.
Subsequently, his mother was found to have features of ocular
albinism indicating an X-linked form of ocular albinism rather
than other conditions associated with chiasmal misrouting such as
Angelman syndrome. He tested negative to mutations in the OA1,
OCA1, OCA2, OCA3, and OCA4 genes. Array comparative
genomic hybridization was also carried out as a screening test for
a child with hypotonia and developmental delay.
The presence of nystagmus and dysmyelinating motor sensory
neuropathy along with central white matter changes on neuroimaging

Figure 2: (a) The lysosomes (black arrows) in the Schwann cell (note the basal lamina [white
arrowhead]) contain lipid with pleomorphic morphology. In this case, the lipid is characterized by
various more or less ill-defined striations, reminiscent of zebra bodies. Scale bar = 500 nm. (b) In
this Schwann cell, the lysosomal lipid storage is in the form of uneven flocculent and focally
vacuolated material and ill-defined radial arrays (arrows). Scale bar = 500 nm.
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Figure 3: Symmetrical cerebral white matter signal abnormalities (white arrowheads) sparing
the subcortical U-fibers were demonstrated on the axial T2 fluid-attenuated inversion recovery
sequence in the brain MRI performed when the patient was 2 years and 11 months old (Figs 3b
and 3d). They were normal when the patient was 11 months old (Figs 3a and 3c).

(i.e., abnormal cerebral white matter signal sparing the subcortical
fibers) prompted testing for Pelizaeus-Merzbacher disease, which
was negative. The presence of significant neurological regression
in our patient guided further investigations. Metachromatic leukodystrophy was considered on the basis of the clinical presentation and abnormal white matter signals within the cerebral
white matter sparing the U fibers on cranial MRI. The diagnosis of
MLD was supported by the low arylsulfatase A activity and urine
sulfatide excretion; however, homozygosity for arylsulfatase
pseudodeficiency alleles in the absence of pathological mutations
did not support the diagnosis.14
As the infant aged, dysmorphic and skeletal features became
more prominent. His coarse facies, skeletal survey findings of
ovoid lumbar vertebra, and skin biopsy pathology, which
demonstrated pleomorphic lysosomal inclusions in Schwann
cells, prompted consideration of a mucopolysaccharidosis. Urine
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mucopolysaccharides excretion was mildly elevated, with
heparan sulfate predominating. A diagnosis of MSD was then
considered and supported by the low levels of activity of multiple
sulfatases in cultured skin fibroblasts. FGE measurement is not
available on a clinical basis. Subsequent confirmation of MSD
was provided by the identification of the two genetic mutations
that result in amino acid substitution (p.A279V and p.R349W).
Eye abnormalities have been previously reported in MSD,
including retinal degeneration and unique, peripheral lens
opacity.3,15 Ocular albinism in our case is unrelated to MSD.
Similarly pseudodeficiency of arylsulfatase A further confounded the
diagnosis of MSD in our case. The phenotype of our patient falls in
the severe spectrum as he is now completely nonresponsive and in a
neuro-vegetative state at age 4 years and 9 months.
The phenotypic spectrum of MSD is caused by the deficiency
of several sulfatases (e.g., neurodegenerative course similar to
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MLD, dysmorphisms and organomegaly as seen in mucopolysaccharidoses, skeletal abnormalities of chondrodysplasia punctata and ichthyosis [X-linked ichthyosis]) and can result in a
confusing clinical presentation; the diagnostic process can be
challenging and often protracted.14,16
The diagnosis of multiple sulfatase deficiency requires a high
index of suspicion when there are clinical features of hypotonia,
developmental delay and regression, skin findings of icthyosis,
and in context of white matter signal abnormalities noted on cranial
MRI. Investigations include urine for elevated mucopolysaccharides
and sulfatides. Skin ultrastructural pathology for inclusions, NCS,
follow-up cranial MRI, and performing a skin biopsy for fibroblast
culture is important for assaying the activity of other sulfatases.
Additionally NCS can be informative. Finally, molecular studies can
confirm the diagnosis. A close collaboration with a biochemical
genetics laboratory will help in planning the investigative work-up in
a complex clinical scenario as in our case.
Schlotawa et al.10,17 analyzed the impact of the p.A279V and
p.R349W mutations and determined that both mutations reduced
the stability of FGE, with the p.R349W being the more severe.
Residual FGE activities in fibroblasts from patients homozygous
for the p.A279V and p.R349W mutations were 23% and 1% of
wild type, respectively. Three patients homozygous for p.R349W
had severe late infantile disease and a patient homozygous for
p.A279V had a milder clinical course. The patient reported here is
a compound heterozygote for p.A279V and p.R349W mutations.
Schlotawa et al.10,17 also reported that fibroblasts from the patient
homozygous for the p.A279V had considerably higher levels of
activity of three sulfatases (arylsulfatase C, galactose-6-sulphatase,
and arylsulfatase A) than did the patients with p.R349W mutations. The activity of two sulfatases, heparan sulfamidase and
iduronyl-2-sulfatase, in cultured fibroblasts from the current
patient are intermediate between the homozygous p.A279V and
p.R349W genotypes reported by Schlotawa et al.12 This is consistent with our patient’s clinical phenotype, which is of late
infantile severe type.
The prognosis is poor for most forms of MSD; the neonatal
presentation is usually fatal within 1 year.4 Enzyme replacement
therapies have been developed for several lysosomal storage diseases. MSD is a lysosomal storage disease; however, the enzyme
that is primarily deficient, FGE, is located in the endoplasmic
reticulum of cells, where it acts posttranslationally on nascent
lysosomal sulfatases. Potential therapies need to enhance the total
residual FGE activity in the endoplasmic reticulum. At present,
management remains largely symptomatic and supportive.
Genetic counselling is recommended for all families.
ADDENDUM
Unfortunately, at time of publication the patient is deceased. At
time of death he was approximately 4 years and 10 months old.
Electronic database information. URLs used in preparation of
this article are:
Locus Link. National Center for Biotechnology Information,
National Library of Medicine (Bethesda, MD), 1999. http://www.
ncbi.nlm.nih.org/LocusLink
Online Mendelian Inheritance in Man, OMIM (TM). Center
for Medical Genetics, Johns Hopkins University (Baltimore, MD)
and National Center for Biotechnology Information, National
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Library of Medicine (Bethesda, MD), 1999. http://www.ncbi.nlm.
nih.gov/omim/
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